Detection of Aspergillus Galactomannan Antigenemia To Determine Biological and Clinical Implications of Beta-Lactam Treatments
Open Access
- 1 October 2005
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (10), 5214-5220
- https://doi.org/10.1128/jcm.43.10.5214-5220.2005
Abstract
Detection of Aspergillus galactomannan (GM) in serum with the Platelia Aspergillus enzyme immunoassay (EIA) is useful for diagnosing invasive aspergillosis. From May 2003 to November 2004, 65 patients who did not develop aspergillosis had at least two positive sera while receiving a beta-lactam treatment (GM index [GMI], ≥0.5). Of the 69 treatment episodes scored, 41 consisted of a beta-lactam other than piperacillin-tazobactam ( n = 29), namely, amoxicillin-clavulanate ( n = 25), amoxicillin ( n = 10), ampicillin ( n = 3), or phenoxymethylpenicillin ( n = 2). In all cases, antigenemia became negative 24 h to 120 h upon stopping the antibiotic. Monitoring of 35 patients, including 26 with hematological malignancies, revealed three antigenemia kinetic patterns: each was observed with any drug regimen and consisted of a persistent GMI of >2.0 (65.7%), >0.5, and ≤1.5 (25.7%) or a variable GMI (14.3%) from the onset of antibiotic therapy. All available drug batches given to 26 patients cross-reacted with the EIA. Galactomannan titration in batches failed to predict the GM titers in the five patients studied at cumulative doses of ampicillin or amoxicillin-clavulanate, regardless of the time lapse between serum sampling and infusion period. Our results show that beta-lactams other than piperacillin-tazobactam may lead to false presumption of aspergillosis. The resulting kinetic patterns of GM antigenemia are variable, and sampling serum prior to the next beta-lactam dose may not decrease GMI below the threshold. Consequently, testing of suspected antibiotic batches remains the only indicator of possible false EIA positivity.Keywords
This publication has 28 references indexed in Scilit:
- False-Positive Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay Results In Vivo during Amoxicillin-Clavulanic Acid TreatmentJournal of Clinical Microbiology, 2004
- Detection of Galactomannan Antigenemia in Patients Receiving Piperacillin-Tazobactam and Correlations between In Vitro, In Vivo, and Clinical Properties of the Drug-Antigen InteractionJournal of Clinical Microbiology, 2004
- False-Positive Aspergillus Galactomannan Antigen Test ResultsClinical Infectious Diseases, 2004
- Reactivity of Platelia Aspergillus Galactomannan Antigen with Piperacillin-Tazobactam: Clinical Implications Based on Achievable Concentrations in SerumAntimicrobial Agents and Chemotherapy, 2004
- Treatment with Piperacillin‐Tazobactam and False‐PositiveAspergillusGalactomannan Antigen Test Results for Patients with Hematological MalignanciesClinical Infectious Diseases, 2004
- False‐Positive Galactomannan PlateliaAspergillusTest Results for Patients Receiving Piperacillin‐TazobactamClinical Infectious Diseases, 2004
- Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detectionThe Lancet, 2004
- False-positive results of Aspergillus enzyme-linked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantationBone Marrow Transplantation, 2001
- Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipientsBone Marrow Transplantation, 1998
- Receptor-Mediated Clearance of Aspergillus GalactomannanThe Journal of Infectious Diseases, 1987